Evidence map›Paper›PMID 30301262›Full record

ArticleInternational journal of molecular sciences2018

Genomic Deletion of

Kadir Harun Sarun, Kenneth Lee, Marissa Williams, Casey Maree Wright, Candice Julie Clarke, Ngan Ching Cheng, Ken Takahashi, Yuen Yee Cheng

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kadir Harun SarunAsbestos Diseases Research Institute, University of Sydney, Sydney, NSW 2139, Australia. kadir.sarun@sydney.edu.au.
Kenneth LeeAsbestos Diseases Research Institute, University of Sydney, Sydney, NSW 2139, Australia. kenneth.Lee@health.nsw.gov.au.
Marissa WilliamsAsbestos Diseases Research Institute, University of Sydney, Sydney, NSW 2139, Australia. marissa.williams@sydney.edu.au.ORCID 0000-0002-0829-7676
Casey Maree WrightAsbestos Diseases Research Institute, University of Sydney, Sydney, NSW 2139, Australia. cmdodds84@gmail.com.
Candice Julie ClarkeAnatomical Pathology Department, Concord Repatriation General Hospital, Sydney, NSW 2139, Australia. Candice.Clarke@health.nsw.gov.au.
Ngan Ching ChengLiver Injury and Cancer Program, Centenary Institute, Sydney, NSW 2050, Australia. ngan.cheng@gmail.com.
Ken TakahashiAsbestos Diseases Research Institute, University of Sydney, Sydney, NSW 2139, Australia. ken.takahashi@sydney.edu.au.ORCID 0000-0002-7310-2257
Yuen Yee ChengAsbestos Diseases Research Institute, University of Sydney, Sydney, NSW 2139, Australia. yycheng@sydney.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant pleural mesothelioma (MPM) is a deadly cancer that is caused by asbestos exposure and that has limited treatment options. The current standard of MPM diagnosis requires the testing of multiple immunohistochemical (IHC) markers on formalin-fixed paraffin-embedded tissue to differentiate MPM from other lung malignancies. To date, no single biomarker exists for definitive diagnosis of MPM due to the lack of specificity and sensitivity; therefore, there is ongoing research and development in order to identify alternative biomarkers for this purpose. In this study, we utilized primary MPM cell lines and tested the expression of clinically used biomarker panels, including CK8/18, Calretinin, CK 5/6, CD141, HBME-1, WT-1, D2-40, EMA, CEA, TAG72, BG8, CD15, TTF-1, BAP1, and Ber-Ep4. The genomic alteration of

Indexed as

AgedAged, 80 and overBiomarkers, TumorCell Line, TumorCells, CulturedCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18Gene DeletionHumansLung NeoplasmsMaleMesotheliomaMesothelioma, MalignantMiddle AgedPrimary Cell CultureTumor Suppressor ProteinsBAP1 protein, humanBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18Tumor Suppressor ProteinsUbiquitin Thiolesterasebiomarkercopy number variationddPCRFISHgenomic deletionmesothelioma

Identifiers

PMID30301262
PMCPMC6213505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.